News from the BioRN Cluster

Home  >>  News from the BioRN Cluster

EMBL: High-res Ebola model could spark new questions

On November 15, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für EMBL: High-res Ebola model could spark new questions

High-res Ebola model could spark new questions By peering into the strands of the Ebola virus (pictured here), researchers were able to create a 3D model of the nucleocapsid. IMAGE: NIAID (CC BY 2.0) EMBL researchers create highest resolution 3D model of important structure within Ebola virus Although the ravages…

Technology Park Heidelberg: Life Science Accelerator-Teams belegen ersten und zweiten Platz des Hightech-Award CyberOne

On November 15, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für Technology Park Heidelberg: Life Science Accelerator-Teams belegen ersten und zweiten Platz des Hightech-Award CyberOne

Life Science Accelerator-Teams belegen ersten und zweiten Platz des Hightech-Award CyberOne Gewinner CyberOne (Bild: Eva-Maria Markutzik) Am Montagabend wurde der Hightech-Preis CyberOne im Europapark Rust verliehen. Der Preis zählt zu den begehrtesten Auszeichnungen des Landes Baden-Württemberg für Hightech-Gründer. Zwei der vom Life Science Accelerator geförderten Teams überzeugten die Jury mit…

Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

On November 14, 2017, Posted by , In Allgemein,News,Press Releases, With Kommentare deaktiviert für Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

miRNA Experts Sign Framework Agreement HEIDELBERG and SAARBRÜCKEN, November 14, 2017 – Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the…

Heidelberg University: Distant Relatives: TOR Protein Regulates Cell Growth in Plants and Animals

On November 10, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Heidelberg University: Distant Relatives: TOR Protein Regulates Cell Growth in Plants and Animals

Plant researchers study gene which – if out of control – can contribute to cancer spread Two such different organisms as plants and humans developed from a common precursor cell. Traces of this over one-billion-year kinship remain anchored in the genetic material of both organisms. An international team of plant…

Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

On November 10, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with innovative novel treatment modalities Leverages MiNA’s leading expertise in RNA…

BioRN Annual Conference 2017 – Joint Forces for Future Innovations

On November 10, 2017, Posted by , In Allgemein,Press Releases, With Kommentare deaktiviert für BioRN Annual Conference 2017 – Joint Forces for Future Innovations

During the BioRN Annual Conference 2017 on October 24, titled “Revolution through Convolution – combining medtech, biotech and digital health to promote health science in our region”, about 120 participants came together from the BioRN Cluster and from the national and international life-science industry, among them representatives of the “Health…

DKFZ: A vaccine against cervical cancer for poor countries

On November 10, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: A vaccine against cervical cancer for poor countries

A novel vaccine against cancer-causing human papillomaviruses (HPV) is intended to help raise vaccination rates especially in developing countries. To this end, scientists from the German Cancer Research Center (DKFZ) in Heidelberg are developing a completely new vaccination concept based on a low-cost vaccine that protects from almost all known…

DKFZ: Misregulated protein breakdown promotes leukemias and brain cancer

On November 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: Misregulated protein breakdown promotes leukemias and brain cancer

An enzyme that is responsible for the breakdown of specific amino acids in food plays a key role in the development of leukemias and brain cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now reported in Nature. The researchers have hence discovered a surprising link between…

Roche: FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation

On November 8, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation

Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has…

Roche: FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

On November 8, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US…

DKFZ: Rare pancreatic cancer reveals targets for therapy

On November 8, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für DKFZ: Rare pancreatic cancer reveals targets for therapy

Scientists from the German Cancer Research Center (DKFZ) have conducted comprehensive molecular analyses of a rare type of pancreatic cancer. They have discovered a variety of cellular alterations that can be targeted by drugs that are already available and in part even already approved for therapy. Malignant growths in the…

Fraunhofer IGB: Faster diagnosis of sepsis pathogens

On November 3, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Fraunhofer IGB: Faster diagnosis of sepsis pathogens

Microbial pathogens can be diagnosed unambiguously and within just 24 hours by means of high-throughput sequencing of their genetic makeup and special bioinformatics evaluation algorithms. Fraunhofer researchers have validated this in a clinical study with sepsis patients. The researchers present the NGS diagnosis platform at Medica in Düsseldorf from November…

Merck: Merck and Samsung BioLogics to Extend Strategic Alliance

On November 1, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Merck: Merck and Samsung BioLogics to Extend Strategic Alliance

01 NOV 2017 | Darmstadt, Germany Alliance on biopharmaceutical manufacturing and biologics processdevelopment Merck would supply Mobius® single-use systems, cell line, cellculture media and chromatography to accelerate biologicsdevelopment Darmstadt, Germany, November 1, 2017 – Merck, a leading science and technology company, today announced the signing of a Memorandum of Understanding…

BioMed X Announces Biomedical Research Collaboration with Janssen

On Oktober 26, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für BioMed X Announces Biomedical Research Collaboration with Janssen

Heidelberg, Germany, October 25, 2017 – BioMed X announced today a collaboration agreement with Janssen Research & Development, LLC (Janssen) to foster early-stage preclinical biomedical research and development projects. Under the agreement, the BioMed X Innovation Center in Heidelberg, Germany will accommodate up to five Janssen research projects. The first…

DKFZ: Sixty-five new genetic risk markers for breast cancer discovered

On Oktober 25, 2017, Posted by , In News, With Kommentare deaktiviert für DKFZ: Sixty-five new genetic risk markers for breast cancer discovered

Until now, familial breast cancer has only partly been linkable to genetic risk markers. In a worldwide joint effort, researchers have now identified further genetic variants that affect the risk for breast cancer. The study, which was conducted with participation of researchers from the German Cancer Research Center (DKFZ) and…

TRANSVAC: European Vaccine Research and Development Infrastructure

On Oktober 17, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für TRANSVAC: European Vaccine Research and Development Infrastructure

TRANSVAC is a new infrastructure project – funded by the European Commission in the context of Horizon 2020 – that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges with the ultimate goal  to build an efficient and sustainable collaboration of experts…

Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

On Oktober 12, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups International Biotech Semifinal of the European Health Catapult Heidelberg, 12 October 2017 On October 4-6, BioRN, together with EIT Health, organized the Biotech Semifinal of the European Health Catapult. The Biotech semifinal consisted of two training days…

Roche: FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus

On Oktober 11, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus

Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses and newborn infants cobas Zika complements efforts to prevent the spread of Zika virus through blood donations in the U.S. cobas Zika expands Roche’s industry-leading donor screening portfolio for blood-borne diseases Roche (SIX: RO, ROG;…

Merck Invests € 35 Million in its Italian Biotech Manufacturing Site of Bari

On Oktober 11, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Merck Invests € 35 Million in its Italian Biotech Manufacturing Site of Bari

New production line for the aseptic filling of biotech medicines under isolator Isolator technology represents best practice for the aseptic filling of injectable medicines and ensures the highest quality standards Investment supports growth of Merck’s portfolio of biotech medicines Bari, Italy, October 3, 2017 – Merck, a leading science and…

Leica Biosystems and Inspirata Sign Agreement to add Aperio Digital Pathology Scanners to Inspirata’s end-to-end Workflow Solution Portfolio

On Oktober 11, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Leica Biosystems and Inspirata Sign Agreement to add Aperio Digital Pathology Scanners to Inspirata’s end-to-end Workflow Solution Portfolio

Leica Biosystems suite of anatomic pathology whole slide scanners will be available as best-of-breed options for the diverse needs of the complex pathology departments served by Inspirata. Washington, DC, October 10, 2017/Globe Newswire – Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has finalized…